Lapatinib is one of tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR/ErbB1) as well as HER2/ErbB2 specifically for treating HER2+ subtypes of breast cancer (54). Here, EGFR is linked to breast carcinoma.